Adamas Pharma (ADMS) Reports Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
Tweet Send to a Friend
Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) today announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine) extended ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
